Adherent cell depletion promotes the expansion of renal cell carcinoma infiltrating T cells with optimal characteristics for adoptive transfer
Background Tumor-infiltrating lymphocyte (TIL) therapy is a personalized cancer treatment which involves generating ex vivo cultures of tumor-reactive T cells from surgically resected tumors and administering the expanded TILs as a therapeutic infusion. Phase 1 of many TIL production protocols use a...
Saved in:
| Main Authors: | Mitchell W Braun, Haitham Abdelhakim, Meizhang Li, Stephen Hyter, Ziyan Pessetto, Devin C Koestler, Harsh B Pathak, Neil Dunavin, Andrew K Godwin |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2020-10-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/8/2/e000706.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes in Advanced Melanoma Patients
by: Mélanie Saint-Jean, et al.
Published: (2018-01-01) -
CD93 blockade promotes effector T-cell infiltration and facilitates adoptive cell therapy in solid tumors
by: Yi Sun, et al.
Published: (2025-01-01) -
Guillain-Barré syndrome after adoptive cell therapy with tumor-infiltrating lymphocytes
by: Thierry Kuntzer, et al.
Published: (2020-10-01) -
Depletion of Regulatory T Cells in a Mouse Experimental Glioma Model through Anti-CD25 Treatment Results in the Infiltration of Non-Immunosuppressive Myeloid Cells in the Brain
by: Wim Maes, et al.
Published: (2013-01-01) -
Adoptive cell therapy with tumor-infiltrating lymphocytes in combination with nivolumab in patients with advanced melanoma
by: D. König, et al.
Published: (2024-12-01)